Pharma Marketing Canada’s Post

Don’t miss the EDETEK Inc. presentation, “Transforming Clinical Trials: From Reactive to Predictive,” during the DPHARM: Disruptive Innovations to Modernize Clinical Research conference Innovative Collaborations Track C, on Tuesday, September 17, 2024, at 4:10pm EDT. “We are leading the trend from a reactive to a predictive approach in clinical trials with a unified, end-to-end platform that connects all stakeholders and automates key processes,” said Munther Baara, VP, Product Strategy & Innovation, EDETEK, Inc. “We will share two use cases of how our clients are leveraging CONFORM. Sites are using our IQ solution in near real time to make rapid clinical decisions, and sponsors are using CONFORM for data acquisition, SDTM and submission production, and data review.” Contact us to set up a meeting at EDETEK Inc. Booth #35 to discuss our CONFORM Platform and its proven ability to orchestrate a superior clinical trial experience through its end-to-end, integrated digital data management solution.     Jian Chen, Peter Smilansky, Michele Cherry, Kevin Prizeman, Craig Lipset, John F. Kouten, Michael W. Young #DPHARM2024 #clinicaltrials #decentralizedtrials #trialdiversity #clinicaldatamanagement #clinicaltrials #clinicaldata  #clinicaloperations #ClinicalResearch #digitaldata #DataScience  #biopharma

Fascinating discussion today with Kevin Landells of IQVIA about the upcoming Innovation Day on May 15th in Princeton, NJ!  If you're passionate about advancing clinical trials, I highly encourage you to attend. Let's work together to ensure smoother, more efficient trials that ultimately deliver life-saving treatments to patients faster. #ClinicalTechnology #ClinicalTrials #IQVIAInnovationDay

Still time to book your place on our 1-hour webinar created for client insight teams! Our experts will share insights from 4 of the presentations showcased as part of Lumanity's recent internal Research Festival. Learn more and register at https://buff.ly/3xCaT51 'The demand for agile and focused research insights comes against a backdrop of growing industry pressures. Staying ahead of the curve not only requires a deep understanding of the intricate interplay of market trends, competitive landscape, and patient needs, but the ability to adapt quickly to changing dynamics.' Presenters include Joel Shopland, Laura Galimam, Mary Stewart, Damian Eade. #Research #Insights #Patients #Pharma #Innovation

If compliance and data quality are vital parameters in your study, then you'd want to hear Olgica Klindworth talk about Clinical Data Studio's Audit Trail Review (ATR) at #MedidataNEXT New York! #solvetheimpossible #MedidataSolutions

We are very excited to introduce LaunchLens, a new syndicated offering from Rosenblatt Life Science Consultants, utilizing Forian Inc. data. 💡📈   Forecasting a product launch entails navigating numerous assumptions, and the uptake curve is a critical factor. LaunchLens provides insights into the time to peak and the shape of an uptake curve for your prospective launch buy leveraging comparable analogs for a more tailored understanding of your products potential. Ensure your uptake curve suits your product’s market and characteristics by refining your set of analogs with our detailed analysis of Forian claims data. 📊✨   Our first offering, Rare LaunchLens, allows you to refine uptake curves using product characteristics such as Efficacy, Safety, Route of Administration Rating, and Level of Unmet Need. Dive deep into the differences in Rare and Ultra-Rare diseases, or understand how a product's safety rating impacts its uptake compared to its efficacy.   📩 Get in Touch: Contact us at [email protected] to learn how you can acquire Rare LaunchLens or discuss a tailored LaunchLens solution for your specific needs.   #Pharma #HealthcareInnovation #RareDiseases #UltraRareDisease #LaunchLens #LifeSciences #DataDrivenInsights #RLSConsultants #Rosenblattlifesciences

Fierce Pharma had an excellent session with Murray Aitken and Anthony Mikulaschek from IQVIA discussing market trends in funding, spending, trial starts, and white space in #clinicaltrials. The white space between phases presents a great opportunity for us to decrease time to market. I've long believed that the future lies in rolling protocols. What strategies do you think can help shorten decision-making and administrative delays? #innovation #clinicalresearch #innovateinwhatyoudo

Excited to take a session on "Enhancing Evidence for Impact and Amplifying Market Access to Key Audiences" during my presentation at #MarCon2024, CIMICON Event Series, Berlin. I’ll be covering two critical topics: - Evidence Generation: What Has Changed? – Exploring how recent advancements have reshaped the landscape of evidence generation in healthcare. - Role of Real-World Evidence (RWE) in Evidence Generation – Highlighting the growing importance of RWE in delivering actionable insights and driving informed decision-making. Looking forward to insightful discussions! #MarketAccess #EvidenceGeneration #RWE #Pharma #HealthcareInnovation #EvidenceBasedMedicine

In today's rapidly evolving healthcare landscape, the importance of measurement and impact cannot be overstated. Accurate measurement not only guides our strategies but also ensures that we deliver tangible value to our partners. With Medscape Outcomes, we're taking this commitment to the next level. At Medscape, we believe that understanding the true impact of educational and promotional efforts is key to making informed decisions and driving positive change. Our performance-based model with Medscape Outcomes offers a transparent and measurable way to ensure success, providing our pharma clients with a new level of certainty and confidence in their investments. Are you interested in discovering how this can work for you? Comment 'YES' below, and we'll reach out with more details! #MedscapeOutcomes #MedscapeGlobal #DigitalHealth

Myth busters on the move again. Check out our latest snippet below!

As we're coming to the end of the first half of the year and seeing so many positive advancements and trial updates from the key congresses like, ASCO, AAN, ISTH, ATS, ASH, EHA, ACMG, and many more... I want to ask the question: In your launch plans, do you feel comfortable with your risk and alternative scenario planning? Do you even have scenario planning included in your launch plans? At Envision Pharma Group, we're launching a new approach to scenario planning called, Envision FutureMap. We're bringing our proven, proprietary methodology to not only identify the potential risk of your launch, but enhance the strategic decision-making through customized response mapping. With so much opportunity to impact the lives of patients with a successful launch, it's only prudent to have plans in place for when or if the unexpected becomes a reality. If you're thinking about scenario planning but need help, let's talk! And if you haven't thought about scenario planning, we should most definitely chat about why you should and how we can help! #medicalaffairs #launchexcellence #riskmanagement #scenarioplanning #envisionpharma #futuremap